Leading with Evidence this Malaria Day

To celebrate World Malaria Day, we’re sharing the article below from BugBitten, the official blog of BioMed Central. Read on for a Q&A with the minds behind ACTwatch, PSI’s multi-country research project designed to fill evidence gaps in malaria. And if you’d like to take a deep dive into the data ACTwatch has collected, check out the

Read More

Achieving the Millennium Development Goal on Malaria: A Q&A with PSI’s Desmond Chavasse

The World Health Organization (WHO) and UN Children’s Fund (UNICEF) recently released a report revealing that the Millennium Development Goal (MDG) “to halt and begin to reverse the incidence” of malaria by 2015 has been met. Malaria-related death rates have plunged by 60% since 2000 and 6.2 million lives have been saved because of global

Read More
APMEN, Malaria, Asia, ACT, ACTwatch

PSI becomes APMEN’s 36th Partner Institution

By: Jenny Tolep, External Relations & Communications PSI was recently announced as the Asia Pacific Malaria Elimination Network’s (APMEN) 36th Partner Institution. Established in 2009, APMEN is a network of 17 Asia Pacific country partners and various partner institutions, working together to eliminate malaria in the region by 2030. APMEN receives funding from the Australian

Read More

Bill Gates Announces Major Funds Increase to Fight Malaria

PSI experts presenting data and leading discussions at 63rd annual meeting

By Mandy McAnally, PSI Bill Gates, co-chair of the Bill & Melinda Gates Foundation, kicked off the 63rd Annual Meeting of the Society of Hygiene and Tropical Medicine in New Orleans, L.A. to a grand ovation. “I really do believe malaria can be eradicated in my lifetime,” he said to a packed ballroom, noting. “I

Read More
Rapid diagnostic tests, filter papers, and blood wells collected as part of a rural plantation worker survey PSI conducted to learn more about the spread of drug-resistant malaria parasites. (Credit: Henrietta Allen)

The Clock is Ticking

Lining up to eliminate a major threat to humankind – Part 3

PSI Senior Vice President for Malaria Control and Child Survival Dr. Desmond Chavasse blogs about his recent trip to Cambodia and PSI’s work to eliminate drug-resistant malaria in Southeast Asia. Below is part 3 of 3. (read part 1 or part 2) PSI, and others, have learned a great deal about malaria in Southeast Asia with the help

Read More
A PSI medical detailer assessing a private provider for Pf malaria diagnosing and treatment capacity. (Credit: Chris James White)

Planting Seeds of Change

Lining up to eliminate a major threat to humankind – Part 2

PSI Senior Vice President for Malaria Control and Child Survival Dr. Desmond Chavasse blogs about his recent trip to Cambodia and PSI’s work to eliminate drug-resistant malaria in Southeast Asia. Below is part 2 of 3. (read part 1) After Bill and Melinda Gates visited PSI in Cambodia, I spent several days there with my

Read More
(Photo credit: PSI/Chris James White)

Seize this Moment

Lining up to eliminate a major threat to humankind – Part 1

PSI Senior Vice President for Malaria Control and Child Survival Dr. Desmond Chavasse blogs about his recent trip to Cambodia and PSI’s work to eliminate drug-resistant malaria in Southeast Asia. Below is part 1 of 3. Why Malaria, Why Southeast Asia, Why now? I first met Bill Gates for dinner in Nairobi in 2008. His

Read More

Evaluating Affordable Medicines Facility—malaria with Through PSI's ACTwatch Pilot

This is a Lancet article published in response to the Affordable Medicines Facility – Malaria (AMFm) evaluation paper (on which PSI supported ACTwatch was second author). Not only does the article acknowledge the contribution of ACTwatch evidence to the AMFm evaluation, it asks why ACTwatch evidence from non AMFm countries was not used as a “control” and it includes a link to the ACTwatch website.

Sarah Tougher and colleagues (Dec 1, p 1916) provide an analysis of the effects of the pilot phase of the Affordable Medicines Facility—malaria (AMFm) in seven countries of sub-Saharan Africa. The paper reports increases in the availability and market share of artemisinin-based combination therapies (ACTs) and price reductions in most countries, and concludes that the AMFm can be effective in rapidly improving these outcomes.

Read More